We aimed to investigate the role of caveolin-1 in papillary thyroid carcinoma pathogenesis.
Study Design
Case series with chart review.
Setting
Institute for the Application of Nuclear Energy.
Subjects and Methods
We evaluated the expression of caveolin-1 in papillary thyroid carcinoma (PTC) by Western blot (WB) and compared the findings with immunohistochemical (IHC) expression of both epithelial and stromal caveolin-1 on the corresponding histological specimens. The results were related to clinicopathological features and BRAF mutation status.
Results
Caveolin-1 expression was found in malignant thyroid epithelium and more abundantly in tumor stroma but varied in both compartments within and between PTC subtypes. Caveolin-1 expression in the epithelium was more intense in classical PTC than in the other histological types. On the contrary, stromal caveolin-1 expression was stronger in the follicular, solid, and trabecular PTC variants than in classical PTC. Trends for down-regulation of caveolin-1 expression in epithelium and up-regulation in stroma from the classical via follicular to the solid variant were observed. The relation of WB and IHC results with clinicopathological parameters showed lower caveolin-1 tissue content in BRAF mutated tumors (P < .05), a positive correlation of epithelial caveolin-1 expression with lymph node metastasis (P < .05), and a negative association of stromal caveolin-1 expression with the degree of neoplastic infiltration and BRAF status.
Conclusion
Altered expression of caveolin-1 in the thyroid epithelial and stromal compartments may be involved in the pathogenesis of PTC. The potential clinical significance of caveolin-1 expression, as well as its relation to BRAF mutation status, deserves further investigation.
CooperDSDohertyGMHaugenBR. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
2.
PelizzoMRMerante BoschinIToniatoA. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol. 2008;33:359-379.
3.
RosenbaumMAMcHenryCR. Contemporary management of papillary carcinoma of the thyroid gland. Expert Rev Anticancer Ther. 2009;9:317-329.
4.
WadaNSuginoKMimuraT. Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation. Ann Surg Oncol. 2009;16:3442-3449.
5.
DaviesHBignellGRCoxC. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
6.
LiXAbdel-MageedABKandilE. BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med. 2012;5:310-315.
7.
WanPTGarnettMJRoeSM. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-867.
8.
CohenYXingMMamboE. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
9.
NambaHNakashimaMHayashiT. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397.
10.
XingM. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
11.
OhoriNPSinghalRNikiforovaMN. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol. 2013;121:197-205.
12.
BasoloFTorregrossaLGianniniR. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95:4197-4205.
13.
CaroniaLMPhayJEShahMH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 2011;17:7511-7517.
14.
EliseiRUgoliniCViolaD. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
15.
KebebewEWengJBauerJ. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466-470.
16.
LeeJHLeeESKimYS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38-46.
17.
XingMClarkDGuanH. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27:2977-2982.
18.
FugazzolaLPuxedduEAveniaN. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006;13:455-464.
19.
ItoYYoshidaHMaruoR. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89-97.
20.
LiuRTChenYJChouFF. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf). 2005;63:461-466.
21.
Basu RoyUKHenkhausRSLoupakisFCremoliniCGernerEWIgnatenkoNA. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. Int J Cancer. 2013;133:43-57.
22.
GoetzJGLajoiePWisemanSMNabiIR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008;27:715-735.
23.
GoetzJGMinguetSNavarro-LeridaI. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011;146:148-163.
24.
OkamotoTSchlegelASchererPELisantiMP. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem. 1998;273:5419-5422.
25.
SowaG. Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front Physiol. 2012;2:120.
26.
ArpaiaEBlaserHQuintela-FandinoM. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 2012;31:884-896.
27.
LajoiePNabiIR. Regulation of raft-dependent endocytosis. J Cell Mol Med. 2007;11:644-653.
28.
PolALuetterforstRLindsayMHeinoSIkonenEPartonRG. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol. 2001;152:1057-1070.
29.
QuestAFGutierrez-PajaresJLTorresVA. Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med. 2008;12:1130-1150.
30.
AldredMAGinn-PeaseMEMorrisonCD. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res. 2003;63:2864-2871.
31.
AldredMAHuangYLiyanarachchiS. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004;22:3531-3539.
32.
ItoYYoshidaHNakanoK. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer. 2002;86:912-916.
33.
JankovicJPaskasSMareckoIBozicVCvejicDSavinS. Caveolin-1 expression in thyroid neoplasia spectrum: comparison of two commercial antibodies. Dis Markers. 2012;33:321-331.
34.
BissellMJRadiskyD. Putting tumours in context. Nat Rev Cancer. 2001;1:46-54.
35.
KalluriRZeisbergM. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
36.
ShahJPAngKBaatenburgRJ. Head and neck. In: EdgeSBByrdDRComptonCCFritzAGGreeneFLTrottiA, eds. AJCC Cancer Staging Manual. 7th ed.New York, NY: Springer-Verlag; 2010:87-96.
37.
SavinSCvejicDIsicTPaunovicITaticSHavelkaM. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol. 2008;39:1656-1663.
38.
SapioMRPoscaDTronconeG. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006;154:341-348.
39.
KimDKimHKooJS. Expression of caveolin-1, caveolin-2 and caveolin-3 in thyroid cancer and stroma. Pathobiology. 2012;79:1-10.
40.
WitkiewiczAKKlineJQueenanM. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle. 2011;10:1794-1809.
41.
KooJSParkSKimSILeeSParkBW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol. 2011;32:787-799.
42.
SloanEKCioccaDRPouliotN. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009;174:2035-2043.
43.
GiatromanolakiAKoukourakisMIKoutsopoulosAMendrinosSSivridisE. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther. 2012;13:1284-1289.
44.
FrascaFNuceraCPellegritiG. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15:191-205.
45.
PatelAKlubo-GwiezdzinskaJHoperiaV. BRAF(V600E) mutation analysis from May-Grunwald Giemsa-stained cytological samples as an adjunct in identification of high-risk papillary thyroid carcinoma. Endocr Pathol. 2011;22:195-199.
